Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.55 |
| ▸ | USP30 | Q70CQ3 | 9/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.46 |
| ▸ | RXRA | P19793 | 2/20 | 0.46 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | RORC | P51449 | 1/20 | 0.44 |
| ▸ | HPGDS | O60760 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12054657 | 1.00 | TACR1 (0.55) | TACR1USP30PDE4BGPR119NR1H2 | |
| SCHEMBL8265031 | 1.00 | TACR1 (0.55) | TACR1USP30PDE4BGPR119NR1H2 | |
| SCHEMBL13617897 | 1.00 | TACR1 (0.55) | TACR1USP30PDE4BGPR119NR1H2 | |
| SCHEMBL2245296 | 1.00 | TACR1 (0.55) | TACR1USP30PDE4BGPR119NR1H2 | |
| SCHEMBL8264378 | 0.94 | TACR1 (0.49) | TACR1USP30PDE4BGPR119NR1H2 | |
| SCHEMBL8265993 | 0.91 | PDE4B (0.55) | TACR1USP30PDE4B | |
| SCHEMBL3195555 | 0.90 | USP30 (0.57) | TACR1USP30PDE4BGPR119PTPN2 | |
| SCHEMBL3195548 | 0.90 | USP30 (0.57) | TACR1USP30PDE4BGPR119PTPN2 | |
| SCHEMBL3201656 | 0.90 | USP30 (0.57) | TACR1USP30PDE4BGPR119PTPN2 | |
| SCHEMBL3195542 | 0.90 | USP30 (0.57) | TACR1USP30PDE4BGPR119PTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389511-B2 | Bicyclic heterocyclic derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-03-05 | — | — | US | disclosed |
| US-20110190278-A1 | BICYCLIC HETEROCYCLIC DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO. | 2011-08-04 | — | — | US | disclosed |
| EP-2243779-A1 | BICYCLIC HETEROCYCLIC DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2010-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190278-A1 | BICYCLIC HETEROCYCLIC DERIVATIVE | REN, AGTR1, AGTR2 | TACR1 157/4885USP30 3836/4885PDE4B 1236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.